已发表论文

弥漫大 B 细胞淋巴瘤合并乙肝病毒感染患者的临床分析和预后意义

 

Authors Kang X, Bai L, Han C, Qi X

Received 31 December 2019

Accepted for publication 28 March 2020

Published 24 April 2020 Volume 2020:12 Pages 2839—2851

DOI https://doi.org/10.2147/CMAR.S244381

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava

Background: China is a high endemic area for the hepatitis B virus (HBV). The studies established the epidemiology between HBV and diffuse large B-cell lymphoma (DLBCL), but further research is necessary to clarify the potential link between HBV and DLBCL.
Patients and Methods: A total of  319 patients diagnosed with DLBCL were recruited as cases at First Medical Centre of Chinese PLA General Hospital from September 2010 to December 2018. During the same time, two age- and sex-matched controls were selected for each case, and the control groups comprised of 319 patients with non-hematological malignancy and 319 subjects with non-malignant conditions. Relative risk of developing DLBCL among individuals tested positive for hepatitis B surface antigen was calculated. After that, we retrospectively analyzed clinical data from DLBCL patients with different HBV infection statuses.
Results: The HBV infection rate of patients with DLBCL (11.60%) was significantly higher than the other two control groups (5.02% and 4.08%), indicating the risk of DLBCL may increased in HBV infections. Meanwhile, this study demonstrated an independent association between HBV infection and poorer clinical outcomes.
Conclusion: Our study demonstrated that HBV infection may play an important role in the pathogenesis of DLBCL and show poor outcomes in HBV-endemic China.
Keywords: case–control study, diffuse large B-cell lymphoma, hepatitis B viral




Figure 5 Overall survival of HBsAg- HBcAb-, HBsAg- HBcAb+...